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We report a case of a 66-year-old African-American female who presented with complaints of progressively worsening weakness,
shortness of breath on minimal exertion, lethargy for the last few days, and short episodes of aphasia lasting 20–30 seconds. Prior
to presentation, she was treated with two courses of moxiﬂoxacin for sinusitis. Laboratory examination was remarkable for anemia
and thrombocytopenia with elevated lactate dehydrogenase and no evidence of renal failure. Peripheral smear showed numerous
schistocytes and she was diagnosed with thrombotic thrombocytopenic purpura. Moxiﬂoxacin was identiﬁed as the oﬀending
agent. The patient was treated with prednisone and plasmapheresis. To the best of our knowledge, this is the ﬁrst reported case of
thrombotic thrombocytopenic purpura associated with the use of moxiﬂoxacin. Although rare, physicians should be aware of this
serious complication associated with its use.
1.Introduction
Thrombotic thrombocytopenic purpura (TTP) is charac-
terized by pentad of thrombocytopenia, microangiopathic
hemolytic anemia, renal function abnormalities, neurologic
symptoms, and fever. It was ﬁrst described by Moschcowitz
in 1925 [1] .N u m e r o u sd r u g sh a v eb e e ni m p l i c a t e di ni t se t i -
ology, the most common being quinine, cyclosporine, ticlo-
pidine, clopidogrel, mitomycin C, bleomycin, cisplatin, gem-
citabine and tacrolimus. Rarely ﬂuoroquinolones (especially
ciproﬂoxacin)havealsobeenassociatedwithTTP[2–4].Flu-
oroquinolones are synthetic antibiotics widely used due to
their broad spectrum coverage, high oral bioavailability, tis-
sue concentrations, and safety proﬁle. We report an unusual
caseof TTP associated with the use of moxiﬂoxacin (Avelox).
2. Case Presentation
A 66-year-old African-American female presented to the
medical ER with complaints of progressively worsening fa-
tigue, shortness of breath on minimal exertion, and lethargy
for the last few days. She also complained of short episodes
ofaphasialasting20–30seconds.Shedeniedfever,chestpain,
sick contacts, blood per rectum, headaches, syncope, or rash.
Her past medical history was signiﬁcant for hypertension,
hypothyroidism, osteoarthritis, and gastroesophageal reﬂux
disease. Home medications included synthroid, telmisartan,
hydrochlorothiazide, aspirin, omeprazole, moxiﬂoxacin, and
ﬂuticasone nasal spray. She denied tobacco, alcohol, or drug
use. Prior to presentation, she had been complaining of sinus
infectionforthelastsixweeksthatwastreatedwithaﬁve-day
course of moxiﬂoxacin. Patient’s symptoms persisted, and
she was started on a second course of moxiﬂoxacin three
days prior to presentation. Vital signs were stable. Physical
examination was notable for systolic ejection murmur. No
petechiae or skin rashes were noted. Neurological exam did
not reveal any cranial nerve, motor, or sensory deﬁcit. Labo-
ratory examination was remarkable for anemia (hemoglobin
of 5.8mg/dL) and thrombocytopenia (platelets less than
10,000/mm3) with lactate dehydrogenase of 744U/L. Her
serum haptoglobin level was low (<20mg/dL; normal 30–
200mg/dL) and reticulocyte count was 6.6%. The patient
had 22% eosinophils, and peripheral smear revealed numer-
o u ss c h i s t o c y t e s( F i g u r e1). Serum creatinine was 1.1mg/dL
(baseline 0.7mg/dL), and total bilirubin was 1mg/dL. Chest
X-ray and CT scan of the head were unremarkable. A clinical2 Case Reports in Medicine
Figure 1: Peripheral smear at admission showing evidence of mi-




















































































Figure 2: Patient’s platelet trend during hospital stay after discon-
tinuation of moxiﬂoxacin and initiation of plasmapheresis.
diagnosis of TTP was made. The patient was admitted
to medical ICU and received a STAT dose of oral pred-
nisone (1mg/kg) along with two units of fresh frozen
plasma and packed red cells while awaiting plasmapheresis.
ADAMTS 13 (a disintegrin-like and metalloprotease with
thrombospondin type 1 repeats) level was low. Review of
medications suggested that moxiﬂoxacin, which was added
recently to the patient’s regimen, most likely precipitated
TTP. Moxiﬂoxacin was discontinued. A double lumen dial-
ysis catheter was placed and plasmapharesis was initiated
and daily plasma exchange was continued. Sepsis was ruled
out with negative sets of blood, urine and sputum cultures,
no leucocytosis, and absence of fever spikes. The patient
showed clinical improvement with plasmapheresis and was
subsequently transferred to medical ﬂoors. Thrombocytope-
nia resolved and anemia improved (platelet of 315,000/mm3;
hemoglobin of 9.7mg/dL) (Figure 2).
3. Discussion
Our patient developed a life-threatening complication relat-
edwiththeuseofmoxiﬂoxacin. Thepresenceofeosinophilia
and recent moxiﬂoxacin use support this. Moxiﬂoxacin
is a ﬂuoroquinolone antibiotic approved for treatment of
adults (≥18 years old) with acute bacterial sinusitis, acute
bacterial exacerbation of chronic bronchitis, community-
acquired pneumonia, skin and skin structure infections, and
complicated intra-abdominal infections caused by suscepti-
bleorganisms[5].Commonsideeﬀectsincludenausea,diar-
rhea,headache,anddizziness.Moxiﬂoxacinisalsoassociated
with increased risk of tendinitis and tendon rupture, exacer-
bation of myasthenia gravis, QT prolongation, hypersensi-
tivity reactions and other serious reactions, including aplas-
tic anemia, agranulocytosis, and pancytopenia [5]. There
areafewreportsofTTPassociatedwiththeuseofquinolones
(especiallyciproﬂoxacin)[2–4],buttothebestofourknowl-
edge, there have been no such reported cases with moxiﬂox-
acin.
The mechanism of ﬂuoroquinolone-induced TTP is
poorly understood and may be secondary to hypersensitivity
reaction. Some authors have postulated that the structural
relationship between ﬂuoroquinolones and quinine (quinine
diﬀers in the addition of a long side chain at position 4
where quinolones have an oxygen molecule) may play a role
[6–8] .T h e s ed r u g sa r ea b l et o“ i m p r o v et h eﬁ t ”b e t w e e n
weakly autoreactive antibodies complementarity determin-
ing regions and target platelet glycoproteins, such as IIb/IIIa
[9], thereby improving the structural and chemical inter-
action. Fluoroquinolone-dependent antibodies against red
blood cells [10, 11] and platelets [11–13] have also been
described. It is also possible that our patient developed
antibodies against moxiﬂoxacin during the initial exposure
that led to TTP during subsequent use. However, the exact
mechanism of moxiﬂoxacin-induced TTP is uncertain.
Moxiﬂoxacin-induced TTP is extremely rare with our
patient being the ﬁrst reported case in the literature. Hyper-
sensitivity reaction can result in TTP as in our patient. Al-
though rare, physicians should be aware of this serious com-
plication associated with its use.
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